Precision NeuroMed
- Company typePrivate
- Founded2024
- HeadquartersRedwood City, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Precision NeuroMed firmographics
Firmographics- Name
- Precision NeuroMed
- Legal name
- Precision NeuroMed
- Website
- https://precisionneuromed.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Precision NeuroMed is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Markets served
Precision NeuroMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- PNM-201 Drug Development and Commercialization: Precision NeuroMed is developing PNM-201 for glioblastoma treatment. As an investigational drug currently in pre-clinical/Phase 1 stages, revenue would be generated through pharmaceutical commercialization upon regulatory approval. The company is also developing the CED Treatment Planning System in partnership with Brainlab for clinical use.
- CED Treatment Planning Platform Licensing: The AI-enabled CED Treatment Planning System will be commercialized through partnership with Brainlab. The platform supports targeted drug delivery and may generate licensing revenue from healthcare providers and treatment centers.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Precision NeuroMed product offering
Product offeringCore offering
Precision NeuroMed develops PNM-201 (IL13-PE38), an investigational drug therapy targeting the IL13a2 receptor on glioblastoma tumor stem cells, currently in pre-clinical/Phase 1 clinical trials. In partnership with Brainlab SE, the company is also commercializing an AI-enabled, cloud-based CED Treatment Planning System that combines molecular flow simulation software with medical imaging to enable precise, standardized convection enhanced delivery of drugs to the brain for neurological conditions including glioblastoma, epilepsy, Parkinson's disease, Alzheimer's disease, and ALS.
Product overview
Precision NeuroMed is a clinical-stage biotechnology company developing targeted drug therapies for neurological diseases. Its primary product is PNM-201 (IL13-PE38), an investigational drug targeting glioblastoma tumor stem cells, currently in clinical trials. The company is also developing a cloud-based CED Treatment Planning System in partnership with Brainlab, an AI-enabled platform that combines molecular flow simulation with medical imaging to optimize convection enhanced delivery treatment planning.
Differentiator
Problem solved
Functional benefit
Products and services
- PNM-201 (IL13-PE38) Investigational drug therapy that selectively targets and kills glioblastoma tumor stem cells expressing the IL13a2 receptor, delivering a potent cytotoxic payload. Currently in pre-clinical/Phase 1 clinical trials for recurrent glioblastoma multiforme.
- CED Treatment Planning System AI-enabled, cloud-based treatment planning platform for convection enhanced delivery (CED) to the brain, combining proprietary molecular flow simulation software with medical imaging to enable precise, standardized drug delivery planning. Designed for healthcare providers and treatment centers treating glioblastoma and other neurological conditions including epilepsy, Parkinson's, Alzheimer's, and ALS.
Quantifiable outcome
- 0 FDA-approved GBM drugs in 20 years prior to PNM-201 development
- +1 more outcomes
Companies that use Precision NeuroMed
Customer profileSegments2 records
Ideal customer profiles2 records
Precision NeuroMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Precision NeuroMed partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Brainlab SEcoreBrainlab SE and Precision NeuroMed announced a strategic partnership to develop and commercialize an AI-enabled convection enhanced delivery (CED) treatment planning system for targeted drug delivery to the brain. Under the joint development agreement, Brainlab received an equity stake in Precision NeuroMed and will combine its medical imaging and surgical workflow expertise with PNM's molecular flow simulation software. The platform will initially support PNM-201 for recurrent glioblastoma before expanding to address epilepsy, Parkinson's, Alzheimer's, and ALS. The companies aim to make CED more standardized, scalable and accessible across community treatment centers.
- Ohio State UniversityminorListed as a partner/expertise collaborator in the company partnerships section, indicating research or development collaboration.
- BayerminorListed as a partner/expertise collaborator in the company partnerships section.
- Cytovance BiologicsminorListed as a partner/expertise collaborator in the company partnerships section.
- AskBiominorListed as a partner/expertise collaborator in the company partnerships section.
- UCSFminorListed as a partner/expertise collaborator in the company partnerships section.
- Cooley LLPminorListed as a partner/expertise collaborator in the company partnerships section, indicating legal or consulting services relationship.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Precision NeuroMed competitors and assessment
Company assessmentDirect peers
- Kazia Therapeutics: Clinical-stage oncology company whose lead asset paxalisib (a PI3K/mTOR inhibitor) is being developed for newly diagnosed and recurrent glioblastoma. Comparable in stage, GBM focus, and need for partnership capital to advance pivotal trials.
- Mustang Bio: Cell and gene therapy company developing CAR-T and lentiviral therapies for hematologic cancers and brain tumors including GBM. Comparable as a small, clinical-stage CNS/cancer biotech pursuing differentiated modalities for high-unmet-need brain tumors.
- Kintara Therapeutics: Clinical-stage oncology company developing VAL-083 for recurrent GBM, with a similar strategic emphasis on underserved recurrent-disease settings. Comparable in stage, GBM focus, and reliance on capital-efficient clinical execution.
- Inovio Pharmaceuticals: Clinical-stage biotech developing DNA-based immunotherapies including candidates for newly diagnosed GBM (INO-5401). Comparable as a clinical-stage company pursuing novel immunologic approaches in glioblastoma.
- DNAtrix: Clinical-stage biotech developing oncolytic virus therapy (DNX-2401) for recurrent glioblastoma. Closely comparable as a small clinical-stage biotech using a novel mechanism to address recurrent GBM with high unmet need.
- Chimerix: Clinical-stage company developing dSTAT (dociparstat sodium) for frontline glioblastoma, with historical focus in CNS oncology. Comparable in stage, oncology focus, and reliance on capital-efficient clinical development in GBM.
Emerging players
- Therataxis: Early-stage company developing convection-enhanced delivery (CED) technologies specifically for brain tumor drug delivery. Direct technological overlap with Precision NeuroMed's CED delivery approach, though smaller and earlier-stage.
Others
- Brainlab SE: Strategic partner and equity holder in Precision NeuroMed. Global provider of medical imaging, surgical navigation, and radiotherapy software/hardware for neurosurgery and oncology. Included as a peer because it is both a partner and the platform on which the CED Treatment Planning System will be commercialized.
Broad incumbents
- ACADIA Pharmaceuticals: Commercial-stage specialty pharmaceutical company focused on CNS disorders including Parkinson's disease psychosis and Rett syndrome. Comparable as a CNS-focused specialty pharma demonstrating the path from clinical-stage CNS biotech to commercial-stage CNS franchise.
- Novocure: Commercial-stage oncology company marketing Tumor Treating Fields (Optune) for newly diagnosed and recurrent glioblastoma. It is the most established commercial player in the GBM treatment space and the closest analog to what a fully-launched Precision NeuroMed could become in recurrent GBM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights6 records
Customer concentration
Precision NeuroMed social profiles
Digital presencePrecision NeuroMed compliance and trust
Trust signalCompliance1 record
Precision NeuroMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precision NeuroMed leadership team
Management profileNumber of profiles
Profiles1 record
Precision NeuroMed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precision NeuroMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precision NeuroMed
What does Precision NeuroMed do?
Precision NeuroMed develops PNM-201 (IL13-PE38), an investigational drug therapy targeting the IL13a2 receptor on glioblastoma tumor stem cells, currently in pre-clinical/Phase 1 clinical trials. In partnership with Brainlab SE, the company is also commercializing an AI-enabled, cloud-based CED Treatment Planning System that combines molecular flow simulation software with medical imaging to enable precise, standardized convection enhanced delivery of drugs to the brain for neurological conditions including glioblastoma, epilepsy, Parkinson's disease, Alzheimer's disease, and ALS.
Is Precision NeuroMed a public or private company?
Precision NeuroMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precision NeuroMed founded?
Precision NeuroMed was founded in 2024. It employs 1 to 10 people.
Where is Precision NeuroMed based?
Precision NeuroMed is headquartered in Redwood City, United States, in the North America region.
How does Precision NeuroMed make money?
Two revenue lines are on record. PNM-201 Drug Development and Commercialization is the primary driver. The others are CED Treatment Planning Platform Licensing.
Who are Precision NeuroMed's main competitors?
Direct peers on record are Kazia Therapeutics, Mustang Bio, Kintara Therapeutics, Inovio Pharmaceuticals, DNAtrix and Chimerix. Therataxis is listed as an emerging player. Brainlab SE is listed as an others. Broad incumbents are ACADIA Pharmaceuticals and Novocure.
Does Precision NeuroMed have an API?
No public API is recorded for Precision NeuroMed.